Canada Markets open in 1 hr 52 mins

Graybug Vision, Inc. (GRAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.3600-0.0200 (-1.45%)
At close: 03:59PM EST
1.3300 -0.03 (-2.21%)
After hours: 06:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.3800
Open1.3800
Bid0.0000 x 4000
Ask0.0000 x 800
Day's Range1.3300 - 1.4399
52 Week Range1.3300 - 35.1800
Volume147,757
Avg. Volume162,370
Market Cap28.995M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline

    BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced the hiring of six new employees who will enhance Graybug’s Research & Development (R&D), Regulatory Affairs and Program Management capabilities, as the Company further builds momentum behind its pipeline in 2022. “We are at a critical stage in our eff

  • GlobeNewswire

    Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

    BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the conference website beginning at 10 a.

  • GlobeNewswire

    Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments

    BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and nine months ended September 30, 2021. Recent Corporate Developments Analysis of Data from Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD —